Lilly Pays $1.2B for Ventyx to Boost Oral NLRP3 Inhibitor Pipeline
Eli Lilly will acquire Ventyx Biosciences for...
The deal bolsters Lilly’s oral inflammation p...
Ventyx’s lead CNS-penetrant NLRP3 inhibitor V...
A second asset, peripheral NLRP3 inhibitor VT...
The deal bolsters Lilly’s oral inflammation p...
Ventyx’s lead CNS-penetrant NLRP3 inhibitor V...
A second asset, peripheral NLRP3 inhibitor VT...










